Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
447 | 3381 | 27.8 | 72% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
335 | 17284 | BLADDER CANCER//CYSTECTOMY//URINARY DIVERSION |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SUPERFICIAL BLADDER CANCER | Author keyword | 179 | 70% | 4% | 147 |
2 | NON MUSCLE INVASIVE BLADDER CANCER | Author keyword | 127 | 69% | 3% | 107 |
3 | BACILLUS CALMETTE GUERIN | Author keyword | 121 | 49% | 5% | 181 |
4 | INTRAVESICAL CHEMOTHERAPY | Author keyword | 113 | 76% | 2% | 78 |
5 | INTRAVESICAL THERAPY | Author keyword | 92 | 64% | 3% | 90 |
6 | BLADDER NEOPLASMS | Author keyword | 77 | 22% | 9% | 313 |
7 | BLADDER CANCER | Author keyword | 63 | 10% | 18% | 594 |
8 | BCG VACCINE | Author keyword | 59 | 37% | 4% | 126 |
9 | BCG | Author keyword | 56 | 21% | 7% | 235 |
10 | T1G3 | Author keyword | 41 | 90% | 1% | 18 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SUPERFICIAL BLADDER CANCER | 179 | 70% | 4% | 147 | Search SUPERFICIAL+BLADDER+CANCER | Search SUPERFICIAL+BLADDER+CANCER |
2 | NON MUSCLE INVASIVE BLADDER CANCER | 127 | 69% | 3% | 107 | Search NON+MUSCLE+INVASIVE+BLADDER+CANCER | Search NON+MUSCLE+INVASIVE+BLADDER+CANCER |
3 | BACILLUS CALMETTE GUERIN | 121 | 49% | 5% | 181 | Search BACILLUS+CALMETTE+GUERIN | Search BACILLUS+CALMETTE+GUERIN |
4 | INTRAVESICAL CHEMOTHERAPY | 113 | 76% | 2% | 78 | Search INTRAVESICAL+CHEMOTHERAPY | Search INTRAVESICAL+CHEMOTHERAPY |
5 | INTRAVESICAL THERAPY | 92 | 64% | 3% | 90 | Search INTRAVESICAL+THERAPY | Search INTRAVESICAL+THERAPY |
6 | BLADDER NEOPLASMS | 77 | 22% | 9% | 313 | Search BLADDER+NEOPLASMS | Search BLADDER+NEOPLASMS |
7 | BLADDER CANCER | 63 | 10% | 18% | 594 | Search BLADDER+CANCER | Search BLADDER+CANCER |
8 | BCG VACCINE | 59 | 37% | 4% | 126 | Search BCG+VACCINE | Search BCG+VACCINE |
9 | BCG | 56 | 21% | 7% | 235 | Search BCG | Search BCG |
10 | T1G3 | 41 | 90% | 1% | 18 | Search T1G3 | Search T1G3 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BACILLUS CALMETTE GUERIN | 271 | 30% | 23% | 761 |
2 | STAGE TA | 185 | 74% | 4% | 139 |
3 | STAGE T1 | 149 | 88% | 2% | 69 |
4 | SUPERFICIAL BLADDER CANCER | 140 | 40% | 8% | 273 |
5 | TRANSITIONAL CELL CARCINOMA | 136 | 14% | 26% | 886 |
6 | INTRAVESICAL THERAPY | 125 | 65% | 4% | 119 |
7 | WHITE LIGHT CYSTOSCOPY | 117 | 76% | 2% | 81 |
8 | BCG IMMUNOTHERAPY | 89 | 60% | 3% | 97 |
9 | IMMEDIATE POSTOPERATIVE INSTILLATION | 77 | 89% | 1% | 34 |
10 | TRANSURETHRAL RESECTION | 76 | 21% | 9% | 319 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder | 2008 | 350 | 48 | 83% |
The mechanism of action of BCG therapy for bladder cancer-a current perspective | 2014 | 16 | 104 | 87% |
Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy | 2009 | 145 | 130 | 81% |
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder | 2013 | 38 | 44 | 89% |
A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group | 2011 | 60 | 38 | 100% |
Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review | 2015 | 2 | 106 | 76% |
Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies | 2010 | 73 | 43 | 86% |
Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses | 2010 | 60 | 49 | 100% |
Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition | 2014 | 6 | 39 | 100% |
Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine | 2013 | 29 | 61 | 80% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BCG ONCOL | 12 | 86% | 0.2% | 6 |
2 | FUNDACIO PUIGVERT | 4 | 17% | 0.7% | 23 |
3 | DEF MED BUR | 3 | 100% | 0.1% | 3 |
4 | CENT PHARMACOVIGILANCE | 2 | 67% | 0.1% | 2 |
5 | EMI 99 09 | 2 | 67% | 0.1% | 2 |
6 | PHARMACOL ANALYT | 2 | 67% | 0.1% | 2 |
7 | RUCT HOSP | 2 | 67% | 0.1% | 2 |
8 | SIDNEY KIMMEL | 2 | 67% | 0.1% | 2 |
9 | ZFKM | 2 | 43% | 0.1% | 3 |
10 | HUMAN EXPT PATHOL | 1 | 31% | 0.1% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000150245 | NMP22//UROVYSION//URINE CYTOLOGY |
2 | 0.0000125051 | PROSTATE SPARING//CYSTOPROSTATECTOMY//RADICAL CYSTOPROSTATECTOMY |
3 | 0.0000117670 | COMPUTER BASED CLASSIFICATION//BLADDER WASHING//TRANSITIONAL CELL BLADDER CANCER |
4 | 0.0000116349 | FGFR3//GENES P53//DBCCR1 |
5 | 0.0000090184 | BLADDER PRESERVATION//BLADDER CANCER//CYSTECTOMY |
6 | 0.0000069532 | WHO ABORAT FOOD NUTR POLICIES//STUDIES MED PROGRAMS SERV//COMPLEX GENET |
7 | 0.0000066659 | MULTIPLE NEUROFIBROMATOSIS//INTRASCROTAL//MALIGNANT NEUROFIBROMA |
8 | 0.0000063764 | VIRTUAL CYSTOSCOPY//BLADDER NEOPLASMS STAGING//BLADDER NEOPLASMS CT |
9 | 0.0000059286 | NEPHROURETERECTOMY//UPPER URINARY TRACT//UPPER TRACT UROTHELIAL CARCINOMA |
10 | 0.0000049459 | Z 100//BCG VIABILITY//NATURAL IMMUNOMODULATOR |